Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neuroendocrine Tumors 7Sarcoma 3Small Cell Lung Carcinoma 2Neoplasms 2Biliary Tract Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Gemcitabine 27Cisplatin 24pembrolizumab 15durvalumab 12Fluorouracil 11Capecitabine 10Oxaliplatin 9Leucovorin 8Bevacizumab 7Carboplatin 5Paclitaxel 4Nivolumab 4Irinotecan 4Injections 4zanidatamab 3trametinib 3lenvatinib 3derazantinib 3atezolizumab 3Ramucirumab 3Docetaxel 3tremelimumab 2surufatinib 2pertuzumab 2gemcitabine-oxaliplatin regimen 2envafolimab 2Trastuzumab 2S 1 (combination) 2Itraconazole 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Biliary Tract Neoplasms × surufatinib × Clear all
NCT03873532 2020-02-13

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Hutchmed

Phase 2/3 Unknown
298 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT02966821 2019-02-27

Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

Hutchmed

Phase 2 Completed
39 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡